Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with <i>EGFR</i>-mutated non-small-cell lung cancer: a retrospective, multicenter cohort study.

ABSTRACT:

Background

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers (NSCLCs) have higher frequencies of bone metastases than those of wild type; however, the metastatic pattern and influence on clinical outcome remain unclear.

Objectives

To analyze the association between bone metastatic sites and the clinical efficacy of the first-, second-, and third-generation EGFR-tyrosine kinase inhibitors (TKI), in these patients.

Design

Retrospective multicenter cohort study.

Methods

The clinical data of patients with advanced-NSCLC harboring EGFR mutation, who were treated by EGFR-TKIs as first-line treatment at five medical institutions (N = 411), were retrospectively assessed for bone metastatic sites, overall survival (OS

SUBMITTER: Tanaka I 

PROVIDER: S-EPMC11662391 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature